The Evolving Understanding of Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is traditionally viewed as a localized, chronic inflammatory skin disease that primarily affects the apocrine gland-bearing regions. However, recent scientific evidence suggests a far more complex reality. Clinicians now increasingly recognize the condition as a multifaceted disorder involving widespread immune dysregulation. This shift in perspective is driven by the observation that systemic inflammation in HS persists even when visible skin lesions appear manageable. For many years, the primary focus of treatment remained on topical therapies and surgical interventions for abscesses and sinus tracts. While these methods address the immediate physical manifestations, they often fail to tackle the underlying inflammatory processes that drive disease progression and associated comorbidities. Understanding the broader systemic impact is essential for improving long-term patient outcomes. Consequently, researchers have turned to advanced proteomic tools to map the inflammatory landscape of the blood. By doing so, they aim to identify specific biomarkers that can guide therapeutic decisions and help predict clinical trajectories. This holistic view is particularly important in the Indian clinical context, where HS is frequently associated with metabolic syndrome and other systemic health challenges that require comprehensive management strategies beyond the skin surface.

Proteomic Mapping: A Deep Dive into HS Mediators

A landmark study utilizing the Olink Target 96 Inflammation panel has provided unprecedented insights into the proteomic profile of HS patients. This research analyzed serum samples from a well-defined cohort, comparing untreated patients against age- and sex-matched healthy controls. Remarkably, the analysis identified thirty-seven distinct inflammatory proteins that were significantly elevated in those with HS. Key mediators identified included Transforming Growth Factor-alpha (TGF-α), Interleukin-6 (IL-6), Oncostatin M (OSM), and Interleukin-17A (IL-17A). Furthermore, the study highlighted significant increases in Hepatocyte Growth Factor (HGF) and Vascular Endothelial Growth Factor A (VEGFA). These findings demonstrate that the inflammatory surge is not confined to the cutaneous tissue but is readily detectable in the systemic circulation. Such a diverse array of cytokines and growth factors suggests that the disease involves multiple immune pathways simultaneously. Specifically, the presence of these markers indicates a state of chronic systemic activation that likely contributes to the high burden of cardiovascular and metabolic comorbidities seen in these patients. By quantifying these proteins, clinicians can move toward a more objective assessment of the total inflammatory load. Therefore, this proteomic mapping serves as a crucial foundation for developing more targeted, systemic-focused therapeutic interventions in the future.

From Mild to Severe: The Gradient of Systemic Markers

One of the most striking findings of the recent proteomic analysis is that systemic inflammation in HS is present even in the earliest stages of the disease. Specifically, mediators such as TGF-α, OSM, and IL-8 were found to be elevated in patients classified with mild (Hurley Stage I) disease. This discovery challenges the conventional approach of delaying systemic therapy until the condition becomes severe or recalcitrant. As the disease progresses to more advanced stages, several inflammatory proteins show a clear, progressive increase. Markers like IL-6, IL-17A, and CCL19 were found to correlate directly with increasing Hurley stages. This gradient suggests that as the cutaneous burden grows, the systemic inflammatory response amplifies accordingly. Moreover, the early elevation of certain markers implies that the pathological process is active long before extensive scarring or sinus tracts develop. Consequently, identifying these early biomarkers could facilitate a window of opportunity for intervention. By treating the systemic aspect of the disease during its mild phase, it may be possible to prevent the irreversible tissue damage associated with chronicity. This evidence reinforces the necessity of a proactive management strategy that acknowledges the systemic nature of HS from the very first diagnosis.

Clinical Correlates: Severity, Quality of Life, and Chronicity

The clinical relevance of these systemic markers is underscored by their strong correlations with patient-reported outcomes and severity scores. In particular, IL-6 and HGF levels showed a significant positive correlation with the International Hidradenitis Suppurativa Severity Score System (IHS4). Additionally, these same proteins were linked to higher Dermatology Life Quality Index (DLQI) scores, indicating a direct relationship between the systemic inflammatory burden and the patient's perceived quality of life. Patients with higher levels of circulating inflammatory mediators often experience more profound physical pain and emotional distress. Furthermore, the study identified that IL-17A and CCL19 are associated with longer disease duration, suggesting they may serve as markers of disease chronicity. This differentiation between markers of acute severity and markers of long-term duration is vital for clinical monitoring. It allows for a more nuanced understanding of how the disease evolves over decades. Since HS is known to have a devastating impact on social and professional life, addressing the systemic drivers of these symptoms is paramount. Consequently, monitoring these specific proteomic signatures could eventually provide a more accurate measure of treatment success than visual inspection of skin lesions alone.

Implications for Early Intervention and Systemic Management

The confirmation of widespread systemic involvement across all disease stages has significant implications for how clinicians should approach HS treatment. Transitioning from a purely reactive model to a comprehensive, early-intervention strategy is now more justified than ever. Because inflammation is already systemic in mild cases, relying solely on topical antibiotics may be insufficient for many patients. Instead, the early introduction of systemic anti-inflammatory agents or biologics could potentially alter the natural history of the disease. Furthermore, these findings support the use of IL-6 and IL-17A as therapeutic targets, given their strong associations with severity and chronicity. In addition to targeting specific cytokines, the data emphasize the need for holistic management that addresses lifestyle factors and comorbidities. Smoking and high Body Mass Index (BMI) are known to exacerbate the inflammatory state, and their management must be integrated into the clinical care plan. By addressing both the biological drivers and the modifiable risk factors, physicians can better mitigate the long-term burden of the disease. Ultimately, the goal is to reduce the risk of permanent scarring and the development of secondary systemic conditions like cardiovascular disease, ensuring a better long-term prognosis for every patient.

Integrating Proteomics into Holistic HS Care in India

In the context of the Indian healthcare system, where the prevalence of metabolic syndrome and diabetes is high, the systemic nature of HS takes on added importance. Studies in Indian cohorts have already established a strong link between HS and metabolic derangements, such as increased waist circumference and fasting blood sugar levels. The recent proteomic data complements these findings by providing a molecular explanation for these associations. Specifically, the systemic elevation of pro-inflammatory cytokines like IL-6 contributes to insulin resistance and atherosclerosis. Therefore, managing an HS patient in India should ideally involve a multidisciplinary team, including dermatologists, internal medicine specialists, and nutritionists. Screening for systemic comorbidities should be a routine part of HS care, regardless of the Hurley stage. Moreover, the use of objective inflammatory markers could help bridge the gap in diagnosis, which is often delayed in the Indian setting. By recognizing the systemic inflammatory signature early, clinicians can advocate for more aggressive management and better resource allocation. This integrated approach not only treats the painful skin lesions but also safeguards the patient's overall health, reducing the risk of long-term disability and improving the overall standard of care for this challenging condition.

Frequently Asked Questions

How does the presence of systemic inflammation change the clinical outlook for patients with early-stage HS?

The discovery of systemic inflammation in early-stage HS indicates that the disease is biologically active throughout the body even before severe skin damage occurs. This suggests that patients with mild symptoms may still be at risk for systemic comorbidities and disease progression. Consequently, clinicians should consider systemic assessments and potentially earlier medical interventions rather than relying only on localized topical treatments to prevent long-term complications and irreversible tissue scarring.

Which specific cytokines correlate most strongly with the severity of hidradenitis suppurativa and patient quality of life?

Research has identified Interleukin-6 (IL-6) and Hepatocyte Growth Factor (HGF) as key proteins that correlate significantly with both the IHS4 severity score and the Dermatology Life Quality Index. These markers reflect the intense inflammatory burden that drives physical symptoms and psychological distress. Monitoring these levels can help clinicians objectively evaluate the impact of the disease on a patient\'s life and guide the selection of more aggressive systemic therapies when necessary.

Why is systemic management considered superior to localized treatment in the context of recent proteomic findings?

Localized treatments only address the cutaneous symptoms, whereas proteomic findings prove that HS involves a broad range of circulating inflammatory mediators. Systemic management, such as the use of biologics or immunomodulators, targets the underlying immune dysregulation at its source. This approach is necessary to reduce the total inflammatory load, manage systemic comorbidities like cardiovascular risk, and provide a more comprehensive resolution of symptoms that localized therapies simply cannot achieve for many patients.

Disclaimer: This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Francke LS et al. Proteomic analysis in hidradenitis suppurativa reveals systemic inflammation in all disease stages. J Eur Acad Dermatol Venereol. 2026 Jun 27. doi: 10.1111/jdv.70546. PMID: 42363729.

Argyropoulou M et al. Genomic and proteomic insights into hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2026 Mar 7. doi: 10.1111/jdv.70390. PMID: 42363729.

Navrazhina K et al. In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes. J Invest Dermatol. 2021 Jul;141(7):1707-1718. doi: 10.1016/j.jid.2020.11.028.